RPG Life Sciences Posts FY2026 Revenue Growth, Profit Decline
Verified article - details checked for accuracy.
Data Extracted via Frism DocuLens
- RPG Life Sciences Limited posted revenue growth of +8.3% YoY to Rs 70,752 lakhs, but profit after tax plunged ‑37% YoY to Rs 11,517 lakhs, pulling EPS down to Rs 69.64 from Rs 110.80.
- Cash & cash equivalents surged to Rs 15,046 lakhs (up from Rs 2,870 lakhs), enabling a final dividend of Rs 24 per share (300% of face value).
- Operating cash flow fell to Rs 5,650 lakhs; profit before tax fell due to higher expenses, labour‑code provisions (Rs 1,169 lakhs) and an intangible write‑off (Rs 916 lakhs), partially offset by a one‑off insurance recovery (Rs 2,475 lakhs).
- Total assets rose 20% to Rs 79,316 lakhs and equity to Rs 60,535 lakhs, while liabilities climbed to Rs 18,781 lakhs, reflecting higher borrowings and trade payables.
- The board approved transferring the API division to the newly created wholly‑owned subsidiary RPG Active Pharma Ltd (pending regulatory consent), aimed at streamlining operations and improving margins.
Complete ArticleExclusive Frism Intelligence Report
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Proudly crafted in India 🇮🇳
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka